|Bid||39.60 x 2200|
|Ask||39.63 x 1100|
|Day's Range||39.57 - 39.64|
|52 Week Range||36.91 - 58.10|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||15.42|
|Forward Dividend & Yield||1.75 (4.59%)|
|Ex-Dividend Date||May 26, 2022|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for SNY
French pharma major Sanofi SA (NASDAQ: SNY) entered into a collaboration and licensing agreement with little-known U.S. biotech miRecule, an innovator of next-generation RNA therapeutics. Under the terms of the deal, Sanofi will develop and commercialize a best-in-class antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD). Sanofi is getting exclusive worldwide rights for the program, known as MC-DX4, while miRecule gets upfront and near-term milestones of about $30 mill
Gaithersburg's miRecule Inc. has inked its first major licensing agreement to bring one new drug to market — and kicked off a Series A funding round to accelerate development of a separate cancer treatment. The company, which develops RNA therapies for drug-resistant cancers and other diseases, announced Tuesday a collaboration with French pharmaceutical giant Sanofi to develop and commercialize a drug for a type of muscular dystrophy with no approved treatments. The deal, worth up to $400 million, would give the clinical-stage biotech its first revenue stream.
Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.